Daly lays down the law at Zyber

Published 16-JUN-2016 16:48 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Newly minted Zyber (ASX:ZYB) CEO Ben Daly has pushed the broom through the company, proclaiming “sales is of the highest urgency right now and I have no tolerance for lack of it”.

He told investors that he had instituted a review of the company upon arriving at the start of the month – saying that ZYB has been lost in a sea of ambiguity.

“Business decisions and statements based on speculative information lead to failed execution, ambiguity in market perception and overall disappointment,” Daly said.

“It’s time to put that ambiguity behind Zyber and move on.”

He said that the product has been ready to go for “some time” – meaning that the product itself doesn’t require ongoing development, setting up ZYB for a sales phase rather than a R&D phase.

Daly has made a suite of changes to the company, including getting rid of the roles of chief technology officer and VP of marketing.

The biggest change though is in the way the company would position itself in the marketplace – being less about being a file sharing product and more about being sold as a ‘Risk Mitigation Solution’.

He said the sales team at Zyber would be given a brief to drive into verticals which are in heavily regulated industries where compliance and risk mitigation are “of the upmost importance”.

Daly also outlined his intention to do away with the company’s current pricing plan and implement a new one which is a combination of license fees, a one time premise set up fee, and four levels of varying features which increase the solution’s price depending on the level of service the customer chooses.

Additionally, he said the company would not enter into white label arrangements – saying they did little to build ZYB’s market share.

In other ZYB news, it said that it had signed a multi-company trial agreement with REDtrac, Wegis & Young, and Water Associates.

All three companies will use the Zyber product to share files securely amongst their employees.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free